AI-generated analysis. Always verify with the original filing.
Acrivon Therapeutics reported fourth quarter and full year 2025 financial results with net loss of $19.0 million and $77.9 million, respectively, and cash of $118.6 million as of December 31, 2025, expected to fund operations into Q2 2027. Highlights include ACR-368 Phase 2b data showing 52% cORR in serous endometrial cancer subjects and initiation of Arm 3 with plans for Arm 4.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition. On March 19, 2026, Acrivon Therapeutics, Inc. (the “Company”) issued a press release announcing its financial r
of this Current Report on Form 8-K. The information contained in Item 2.02 and Item 7.01, including Exhibit 99.1 and 99.2, shall not be deemed “filed” for purpo
Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated March 19, 2026 99.2 Acrivon Therapeutics, Inc., Corporate Presentation 10
| Metric | Value | Basis |
|---|---|---|
| Net loss | $-19.00 | GAAP |
| Net loss | $-77.90 | GAAP |
| Net loss per share - basic and diluted | $-0.49 | GAAP |
| Net loss per share - basic and diluted | $-2.02 | GAAP |
| Research and development expenses | $14.70 | GAAP |
| Research and development expenses | $60.00 | GAAP |
| General and administrative expenses | $5.40 | GAAP |
| General and administrative expenses | $24.10 | GAAP |